<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="218384">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241605</url>
  </required_header>
  <id_info>
    <org_study_id>712753/008</org_study_id>
    <nct_id>NCT00241605</nct_id>
  </id_info>
  <brief_title>AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus</brief_title>
  <official_title>AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 48-week study will compare AVANDAMET vs. Metformin monotherapy for blood glucose
      control in patients with Type 2 Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c at week 48.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FPG at week 48. Time to glycemic control. Change from baseline in C-peptide and insulin at week 48.</measure>
  </secondary_outcome>
  <enrollment>600</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone/metformin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 and 75 years of age with Type 2 Diabetes Mellitus and are
             currently on metformin monotherapy for glycemic control (100mg daily for at least 3
             months prior to screening).

          -  Patients must have stopped previous treatment with thiazolidinediones or other
             anti-diabetic agents at least 3 months prior to screening.

          -  Women must be post-menopausal, surgically sterile or using acceptable contraceptive
             measures.

        Exclusion Criteria:

          -  Prior history of hepatocellular reaction to or severe edema associated with the use
             of thiazolidinediones.

          -  Have a known hypersensitivity to thiazolidinediones or biguanides.

          -  Currently using insulin or any oral anti-diabetic agent other than metformin.

          -  History of metabolic acidosis.

          -  History of substance abuse.

          -  Have active cancer other than localized squamous or basal cell carcinoma.

          -  Chronic disease requiring treatment with corticosteroids.

          -  Other criteria will be evaluated at the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 11, 2013</lastchanged_date>
  <firstreceived_date>October 17, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>AVANDAMET</keyword>
  <keyword>Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
